Navigation Links
Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting

WOODCLIFF LAKE, N.J., May 15 /PRNewswire/ -- Eisai Corporation of North America announced today that results from 16 clinical data abstracts about compounds in the company's oncology pipeline, product portfolio and preclinical oncology research have been accepted for presentation at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago from May 30 to June 3, 2008.

A wide variety of abstracts on Eisai marketed products and investigational compounds will showcase research focused on metastatic breast cancer, lung cancer, ovarian cancer, brain cancer, mesothelioma, pancreatic cancer, myelodysplastic syndromes and other types of cancer, as well as supportive care to aid those currently undergoing treatment for cancer.

"Eisai's commitment to oncology is clearly translating into the substantial growth of our pipeline," said Haruo Naito, President and CEO, Eisai Co., Ltd. "Eisai's focus on becoming a global leader in oncology reflects our human health care mission to satisfy unmet medical needs and increase benefits to patients and their families."

The following Eisai abstracts are accepted for presentation at this year's ASCO meeting.

Product Abstract Details Location Details

MORAb-003 Exploratory Phase II Efficacy June 1, 2008

(farletuzumab) Study of MORAb-003, a Monoclonal 4:30-4:45 p.m.

Abstract No: 5500 Antibody against Folate Receptor Location: S406

Alpha, in Platinum-Sensitive (Vista Room)

Ovarian Cancer in First Relapse

Oral Presentation

E7080 A phase I study of E7080 in May 31, 2008

Abstract No: 3526 patients with advanced 8:00 a.m.

malignancies -12:00 p.m.

Location: W375E


Poster 3 Poster

Awarded a Foundation Merit Award discussion

12:00-1:00 p.m.

Location: W375A

E7080 Phase I dose escalation study May 31, 2008

Abstract No: 3527 and biomarker analysis of 8:00 a.m.

E7080 in patients with -12:00 p.m.

advanced solid tumors Location: W375E

Poster 4 Lobby



12:00-1:00 p.m.

Location: W375A

Cutaneous T-cell (Integrated analysis of three May 31, 2008

Lymphoma large Phase III trials in CTCL) 8:00 a.m.

Abstract No: 8551 Poster 45A -12:00 p.m.

Location: S Hall


MORAb-003 A Phase I Study of MORAb-003, May 31, 2008

(farletuzumab) a Humanized Monoclonal Antibody 2:00-6:00 p.m.

Abstract No: 5517 Against Folate Receptor Alpha, Location: S403

in Advanced Epithelial Poster

Ovarian Cancer discussion

Poster 7 5:00-6:00 p.m.

Location: S406

(Vista Room)

ALOXI(R) Palonosetron (PALO) for May 31, 2008

(palonosetron HCl) Prevention of Chemotherapy- 2:00-6:00 p.m.

Abstract No: 9617 induced Nausea and Vomiting Location: S Hall

in Patients Receiving High- A1

dose Melphalan Prior to

Stem Cell Transplant

Poster 46B

GCP II Inhibitor Glutamate Carboxypeptidase II May 31, 2008

Abstract No: 9558 Inhibition in Rat Models of 2:00-6:00 p.m.

Chemotherapy-induced Location: S Hall

Peripheral Neurotoxicity A1

Poster 37A

E7820 A phase I study of E7820 in June 1, 2008

Abstract No: 3568 combination with cetuximab in 2:00-6:00 p.m.

patients (pts) with advanced Location: S Hall

solid tumors A1

Poster 24G

MORAb-009 A Phase I Study of MORAb-009, June 1, 2008

Abstract No: 3578 a Monoclonal Antibody against 2:00-6:00 p.m.

Mesothelin, in Mesothelioma, Location: S Hall

Pancreatic, and Ovarian Cancer A1

Poster 27C

Eribulin Phase II Study of Eribulin June 2, 2008

Mesylate (E7389) Mesylate (E7389) in Patients 2:00-6:00 p.m.

Abstract No: 1084 with Locally Advanced or Location: S Hall

Metastatic Breast Cancer A1

Previously Treated with

Anthracycline, Taxane, and

Capecitabine Therapy

Poster 38A

Advanced Breast Oncologist and Patient Roles in June 2, 2008

Cancer Assessing Current and Future 2:00-6:00 p.m.

Abstract No: 1064 Treatment for Metastatic Location: S Hall

Breast Cancer: Results of an A1

Observational Linguistic study

Poster 32B

DACOGEN(R) A Multicenter Phase II Trial of June 2, 2008

(decitabine) the Decitabine Alternative 2:00-6:00 p.m.

Abstract No: 7032 5-day Dosing Regimen: Analysis Location: E450A

of Efficacy in Various

Subgroups of Patients with Poster

Myelodysplastic Syndromes discussion

Poster 21 5:00-6:00 p.m.

Location: E354A

DACOGEN(R) Cytogenetic Responses to a June 2, 2008

(decitabine) 5-Day Dosing Schedule of 2:00-6:00 p.m.

Abstract No: 7030 Decitabine in Patients with Location: E450A

Myelodysplastic Syndromes

Poster 19 Poster


5:00-6:00 p.m.

Location: E354A

ALOXI(R) Palonosetron (PALO) versus Accepted for

(palonosetron granisetron (GRAN), both publication

HCl) combined with dexamethasone only.

(DEX) in preventing

chemotherapy-induced nausea

and vomiting (CINV) associated

with cisplatin- or anthracycline

plus cyclophosphamide-based

regimens: Results of a Phase III

trial in Japanese patients

ALOXI(R) Palonosetron (PALO), administered Accepted for

(palonosetron orally or intravenously (IV), publication

HCl) plus dexamethasone for prevention only.

of chemotherapy-induced nausea

and vomiting (CINV)

GLIADEL(R) Wafer Treatment of Adults with Newly Accepted for

(polifeprosan 20 Diagnosed Glioblastoma publication

with carmustine Multiforme or Anaplastic only.

implant) Astrocytoma with Surgery, Gliadel

Wafers and Limited Field

Radiation Plus Concomitant

Temozolomide Followed by

Adjuvant Temozolomide

Eisai began its oncology research program in 1987, discovering several small molecules that are in development as chemotherapeutic agents. In addition to its in-house oncology research and development (R&D) program, Eisai made three strategic acquisitions to establish a solid business infrastructure and enter the U.S. oncology market.

In October 2006, Eisai acquired four products mainly for the treatment of cutaneous T-cell lymphoma, as well as an oncology specialty sales force from Ligand Pharmaceuticals. This provided Eisai with an initial commercial infrastructure for oncology products. The acquisition of Morphotek, Inc. in April 2007 added important antibody technology and an antibody pipeline. In January 2008, Eisai acquired MGI PHARMA, INC., an oncology and acute care-focused company, to broaden its R&D and commercial capabilities, pipeline and product portfolio in oncology and supportive care.

Eisai is committed to addressing the unmet medical needs of patients with cancer and to delivering novel treatment options that create hope.

About Aloxi Injection

Aloxi is approved by the U.S. FDA for the prevention of acute nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy and for the prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. Aloxi is the first and only 5-HT(3) receptor antagonist to be indicated for the prevention of delayed CINV caused by moderately emetogenic cancer chemotherapy.

The most common adverse reactions related to Aloxi were headache (9%) and constipation (5%). Aloxi is contraindicated in patients known to have hypersensitivity to the drug or any of its components.

Please see the Aloxi package insert, available at, for important additional details.

About Gliadel Wafer

Gliadel (polifeprosan 20 with carmustine implant) Wafer is indicated in patients with newly diagnosed high-grade malignant glioma as an adjunct to surgery and radiation. Gliadel is also indicated in patients with recurrent glioblastoma multiforme as an adjunct to surgery.

Gliadel should not be given to individuals who have demonstrated a previous hypersensitivity to carmustine or any of the components of Gliadel. Patients undergoing craniotomy for malignant glioma and implantation of Gliadel should be monitored closely for complications of craniotomy, including seizures, intracranial infections, abnormal wound healing and brain edema.

Communication between the surgical resection cavity and the ventricular system should be avoided to prevent the wafers from migrating into the ventricular system and causing obstructive hydrocephalus. If a communication larger than the diameter of a wafer exists, it should be closed prior to wafer implantation. Computed tomography and magnetic resonance imaging of the head may demonstrate enhancement in the brain tissue surrounding the resection cavity after implantation of Gliadel. This enhancement may represent edema and inflammation caused by Gliadel or tumor progression. The short-term and long- term toxicity profiles of Gliadel, when given in conjunction with chemotherapy have not been fully explored.

Please visit or for full prescribing information.

About Dacogen

Dacogen (decitabine) for Injection was approved by the U.S. Food and Drug Administration on May 2, 2006 and is indicated for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British (FAB) subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, chronic myelomonocytic leukemia), and Intermediate-1, Intermediate-2 and High-Risk International Prognostic Scoring System (IPSS) groups.

Dacogen may cause fetal harm when administered to a pregnant woman. Women of childbearing potential should be advised to avoid becoming pregnant while using Dacogen. Men should be advised not to father a child while receiving treatment with Dacogen and for two months afterwards. The most commonly occurring adverse reactions with Dacogen include neutropenia (90%), thrombocytopenia (89%), anemia (82%), pyrexia (53%), fatigue (48%), nausea (42%), cough (40%), petechiae (39%), constipation (35%), and diarrhea (34%).

Please visit or for full prescribing information.

About Eisai Corporation of North America

Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: neurology, gastrointestinal disorders and oncology/critical care.

Eisai Corporation of North America supports the activities of its operating companies in North America, which include: Eisai Research Institute of Boston, Inc., a discovery operation with strong organic chemistry capabilities; Morphotek, Inc., a biopharmaceutical company specializing in the development of therapeutic monoclonal antibodies; Eisai Medical Research Inc., a clinical development group; Eisai Inc., a commercial operation with manufacturing and marketing/sales functions; MGI PHARMA, INC., an R&D and commercial operation with manufacturing and marketing/sales functions; and Eisai Machinery U.S.A., which markets and maintains pharmaceutical manufacturing machinery.

SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. GeoVax Secures $10 Million Financing Commitment
2. On Second Anniversary, Compendia Bioscience Announces Significant Revenue Growth, Completion of Product Milestone and Expansion of Pharma Customer Commitments
3. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
4. BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
5. Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting
6. Release of Cytopia Abstract for CYT997 Oral Presentation at American Society of Clinical Oncology
7. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
8. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
9. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
10. GlaxoSmithKline Reports Further Progress of Oncology Portfolio
11. Roche Gains Access to Important Oncology Target With Potential for Treating Major Cancers Such as Breast and Lung; First Drug Candidate in Phase I Clinical Testing
Post Your Comments:
(Date:10/12/2015)... A new computer program that analyzes functional brain MRIs ... develop effective language skills within two years of cochlear ... Brain and Behavior . ... 12 online edition, researchers at Cincinnati Children,s Hospital Medical ... of the brain respond to auditory stimulus tests that ...
(Date:10/12/2015)... 2015  To help address the growing opioid epidemic ... Surgeons (AAOS) Board of Directors is calling for ... patient education; the tracking of opioid prescription use; research ... effective opioid abuse treatment programs. David Ring ... Safety Committee. "The new , AAOS Information Statement on ...
(Date:10/12/2015)... , Oct. 12, 2015  Today, Divurgent is honored to ... Services. As a former CIO, Paul brings 15 years of ... understand or sympathize with today,s CIOs, he is one. The ... challenges Paul has faced, and his new role with Divurgent ... technology efficiencies across an organization. ...
Breaking Medicine Technology:
(Date:10/13/2015)... Miami, FL (PRWEB) , ... October 13, 2015 , ... ... announces the Driveway Snow Blanket, a snow melting invention that helps people in clearing ... $17 billion and will continue to grow at 3.8% per year," says Scott Cooper, ...
(Date:10/13/2015)... ... 2015 , ... With Fall weather approaching and holiday travel season upon us, ... Styler Contest. , Enter to win! , How to Enter:, 1. Like ... Style? , 3. Follow us on Instagram @thebeautyplace , 4. Share Facebook Contest ...
(Date:10/13/2015)... ... , ... Just under three months ago, eMarketing Concepts forever changed ... effectively offering all of their services for just a buck in the first month. ... phone calls from interested buyers. As a genuine one-stop-shop for internet marketing, EMC has ...
(Date:10/13/2015)... Virginia (PRWEB) , ... October ... ... International Biotechnology, LLC presented results from GyencoloGeneTM, the world’s first commercially-available next-generation ... the XXI FIGO World Congress of Gynecology and Obstetrics in Vancouver, BC, ...
(Date:10/12/2015)... (PRWEB) , ... October 13, 2015 , ... North American ... (IBC) at the 2015 IBC National Meeting in Rosemont, IL on October 4th. ... dedication, quality, and standards of excellence that customers have come to expect from members ...
Breaking Medicine News(10 mins):